Boston Scientific (NYSE:BSX) Shares Up 9.4% on Strong Earnings

Boston Scientific Corporation (NYSE:BSX) shares shot up 9.4% during trading on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $65.20 and last traded at $65.1110. 11,261,906 shares traded hands during trading, a decline of 28% from the average session volume of 15,676,979 shares. The stock had previously closed at $59.52.

The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat and solid top-line growth — Q1 revenue of ~$5.20B and adjusted EPS $0.80 topped estimates and showed 11.6% sales growth, which underpins the bullish reaction. Boston Scientific announces results for first quarter 2026
• Positive Sentiment: Analysts largely kept Buy ratings and reaffirmed long‑term upside (Jefferies, Barclays kept constructive views despite trimming PTs), supporting investor confidence. Balancing Near-Term Guidance Cuts With Long-Term Growth Drivers
• Neutral Sentiment: Several firms trimmed price targets (e.g., Barclays, Jefferies, Stifel lowered PTs to ~$85–$100) — still implying meaningful upside from current levels, but reflecting a nearer‑term reset. Benzinga coverage of analyst updates
• Neutral Sentiment: Unusually large options activity and heavy trading volume signaled speculative and institutional positioning into the print, adding to intraday momentum. Why Is Boston Scientific Stock Soaring Wednesday?
• Negative Sentiment: Management cut FY‑2026 and Q2 guidance (EPS and revenue ranges came in below consensus), which is a clear headwind for near‑term expectations. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Multiple class‑action lawsuits and investor alerts were filed/announced, creating legal overhang and potential costs or distraction for management. BSX Investor Alert: Securities Fraud Lawsuit

Wall Street Analyst Weigh In

Several analysts recently commented on BSX shares. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. TD Cowen lowered their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Weiss Ratings cut Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. Argus upgraded Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Finally, Mizuho lowered their target price on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.04.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. State Street Corp boosted its stake in shares of Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares in the last quarter. Capital World Investors boosted its stake in shares of Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after acquiring an additional 502,627 shares in the last quarter. Norges Bank bought a new stake in shares of Boston Scientific during the 4th quarter worth $2,199,395,000. Finally, Morgan Stanley boosted its stake in shares of Boston Scientific by 10.8% during the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after acquiring an additional 2,246,308 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Up 9.1%

The firm has a market capitalization of $96.53 billion, a P/E ratio of 33.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm has a 50 day moving average price of $68.87 and a two-hundred day moving average price of $86.16.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.